{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:01:54Z","timestamp":1769090514564,"version":"3.49.0"},"reference-count":79,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T00:00:00Z","timestamp":1358812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:p>By using the <jats:styled-content style=\"fixed-case\">GRADE<\/jats:styled-content> system, we updated the guidelines for management of follicular cell lymphoma issued in 2006 from <jats:styled-content style=\"fixed-case\">SIE<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">SIES<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">GITMO<\/jats:styled-content> group. We confirmed our recommendation to frontline chemoimmunotherapy in patients with Stage <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> disease and\/or high tumor burden. Maintenance rituximab was also recommended in responding patients. In patients relapsing after an interval longer than 12 months from frontline therapy, we recommended chemoimmunotherapy with non cross\u2010resistant regimens followed by rituximab maintenance. High dose chemotherapy followed by hematopoietic stem cell transplant was recommended for young fit patients who achieve a response after salvage chemoimmunotherapy. Am. J. Hematol. 88:185\u2013192, 2013. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23372","type":"journal-article","created":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T07:32:32Z","timestamp":1355297552000},"page":"185-192","source":"Crossref","is-referenced-by-count":30,"title":["<scp>SIE<\/scp>, <scp>SIES<\/scp>, <scp>GITMO<\/scp> revised guidelines for the management of follicular lymphoma"],"prefix":"10.1002","volume":"88","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[{"name":"Istituto di Ematologia ed Oncologia Medica \u201cSeragnoli,\u201d Universit\u00e0 di Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monia","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Ematologia Ospedale Cardinal Massaia Asti Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atto","family":"Billio","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Ematologia Ospedale Civile di Bolzano Bolzano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Epidemiology and Center of the Study of Myelofibrosis Fondazione IRCCS Policlinico San Matteo Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia I IRCCS Azienda Ospedaliera Universitaria San Martino Genova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Lazzarino","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia Fondazione IRCCS Policlinico San Matteo Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Biotecnologie Cellulari ed Ematologia Cattedra di Ematologia Universit\u00e0 La Sapienza Roma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia Spedali Riuniti Bergamo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[{"name":"Unit of Hematology AOU Careggi University of Florence Firenze Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia Ospedale Mauriziano Torino Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia Azienda Ospedaliera San Giovanni Battista Torino Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sante","family":"Tura","sequence":"additional","affiliation":[{"name":"Department of Hematology University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,22]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"1237","article-title":"Management of nodal indolent (non marginal\u2010zone) nonHodgkin's lymphoma: Practice guidelines from the Italian Society of Haematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation","volume":"90","author":"Barosi G","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2005.12.005"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_7_5_1","first-page":"460","article-title":"The NIH consensus development program. The evolution of guidelines","volume":"12","author":"Ferguson JH","year":"1996","journal-title":"Int J Technol Assess Health Care"},{"key":"e_1_2_7_6_1","first-page":"1576","article-title":"SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia","volume":"34","author":"Mauro FR","year":"2010","journal-title":"Leuk Res"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529208"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22807"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2778"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.040"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1539-5"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701422059"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011169332265"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.48.1856"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.09.051"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21967"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.005"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.013"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0958-z"},{"key":"e_1_2_7_21_1","first-page":"958","article-title":"18F\u2010FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta\u2010analysis","volume":"46","author":"Pakos EE","year":"2005","journal-title":"J Nucl Med"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2490"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0852"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2332"},{"key":"e_1_2_7_28_1","first-page":"6","article-title":"An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non\u2010bulky follicular lymphoma (grades 1, 2 and 3a","volume":"116","author":"Ardeshna K","year":"2010","journal-title":"A preliminary analysis. Blood (ASH Annual Meeting Abstracts"},{"key":"e_1_2_7_29_1","first-page":"19","article-title":"Preliminary results of quality of life (QOL) analyses from the intergroup phase III randomized trial of Rituximab vs","volume":"22","author":"Ardeshna KM","year":"2011","journal-title":"a watch and wait approach in patients with advanced stage, asymptomatic, non\u2010bulky follicular lymphoma (FL). Ann Oncol"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.05.013"},{"key":"e_1_2_7_31_1","first-page":"584","article-title":"Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R\u2010MCP) versus MCP alone in untreated advanced indolent non\u2010Hodgkin's lymphoma (NHL) and MantleCell\u2010lymphoma (MCL","volume":"104","author":"Herold M","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_33_1","first-page":"2599","article-title":"Rituximab in combination with CHOP in patients with follicular lymphoma: Analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58 months","volume":"112","author":"Buske C","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_35_1","first-page":"135","article-title":"R\u2010CVP vs. R\u2010CHOP vs. R\u2010FM for the initial treatment of patients with advanced stage follicular lymphoma. Preliminary results of FOLL05 trial","volume":"22","author":"Federico M","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_7_36_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V114.22.405.405","article-title":"Bendamustine plus rituximab in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first\u2010line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the AtiL (Study Group Indolent Lymphomas, Germany","volume":"114","author":"Rummel M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr450"},{"key":"e_1_2_7_38_1","first-page":"4004","article-title":"Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL","volume":"111","author":"Ladetto M","year":"2008","journal-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R\u2010HDS) versus conventional (CHOP\u2010R) chemoimmunotherapy in high\u2010risk follicular lymphoma at diagnosis: The superior disease control of R\u2010HDS does not translate into an overall survival advantage. Blood"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.0736"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0529"},{"key":"e_1_2_7_45_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3056.3056","article-title":"R\u2010FND followed by radioimmunotherapy for high\u2010risk follicular lymphoma","author":"McLaughlin P","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.044"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr145"},{"key":"e_1_2_7_48_1","first-page":"32953301","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"Oers M","year":"2006","journal-title":"Blood"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr418"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5358"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.8327"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4204"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn044"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.594925"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030320"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.035"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705849"},{"key":"e_1_2_7_61_1","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high\u2010dose therapy as in vivo purging and to maintain remission following high\u2010dose therapy","author":"Pettengell R","journal-title":"ASCO Annual Meeting 2010"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136242"},{"key":"e_1_2_7_63_1","first-page":"1176","article-title":"GELTAMO Group","volume":"95","author":"Pi\u00f1ana JL","year":"2010","journal-title":"Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: Long term follow\u2010up from two prospective multicenter trials. Haematologica"},{"key":"e_1_2_7_64_1","first-page":"3695","volume":"28","author":"Thomson KJ","year":"2010","journal-title":"T\u2010cell depleted reduced\u2010intensity transplantation followed by donor leukocyte infusions to promote graft\u2010versus lymphoma activity results in excellent long\u2010term survival in patients with multiply relapsed follicular lymphoma J Clin Oncol"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07905.x"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.11.004"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.055"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"key":"e_1_2_7_70_1","doi-asserted-by":"crossref","first-page":"615s","DOI":"10.1200\/jco.2004.22.90140.6732","article-title":"The iodine 1\u2013131 tositumab therapeutic regimen: Summary of safety in 995 patients with relapsed\/refractory low grade (LG) and transformed LG non\u2010Hodgkin's lymphoma. (abs.6732)","volume":"22","author":"Gregory SA","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_71_1","unstructured":"NCCN Clinical PracticeGuidelines in Oncology (NCCNTM). Non\u2010Hodgkin's Lymphomas. Ves 4.2011. Available at:www.nccn.org. Accessed on November 21 2011."},{"key":"e_1_2_7_72_1","first-page":"446","article-title":"On behalf of the British Committee for Standards in Haematology","volume":"156","author":"Mc Namara C","year":"2012","journal-title":"Guidelines on the investigation and management of follicular lymphoma. Br J Haematol"},{"issue":"6","key":"e_1_2_7_73_1","first-page":"59","article-title":"on behalf of the ESMO Guidelines Working Group","volume":"22","author":"Dreyling M","year":"2011","journal-title":"Newly diagnosed and relapsed follicular lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow\u2010up. Ann Oncol"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.01.008"},{"key":"e_1_2_7_75_1","first-page":"147","article-title":"Consensus conference on the use of 90\u2010yttrium\u2010ibritumumab tiuxetan therapy in clinical practice","volume":"85","author":"Vitolo U","year":"2009","journal-title":"A project of the Italian Society of Hematology. Am J Hematol"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701769665"},{"key":"e_1_2_7_77_1","first-page":"1025","article-title":"Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal","volume":"23","author":"Braga P","year":"2010","journal-title":"Acta Med Port"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta13suppl1\/04"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq582"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802120028"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23372","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:25:45Z","timestamp":1697448345000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,22]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1002\/ajh.23372"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23372","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,22]]}}}